The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. RESULTS: Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS: Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inter- and intra-driver heterogeneity are also evident following treatment with inhibitors of the immune checkpoint molecules PD-1 or PD-L1, with only ~20% of unselected NSCLC patients deriving durable clinical benefit38–43.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [39]
In the citing paper
“other features such as TMB appear to also be associated with clinical benefit to PD-1 / PD-L1 antibodies”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I. O., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 758
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W. J., Paz-Ares, L. G., & Schmid‐Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 315
Self-citationPennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 320
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 325
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A. R., & Boland, G. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 330
Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E. G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., Brighenti, M., et al. (2020) · Cancers · doi:10.3390/cancers12030546 · Cited by 300
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J., Pasero, P., & Postel-Vinay, S. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 306
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 297
Zerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 305
Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., De Marinis, F., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz094 · Cited by 262
Wallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 294
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Self-citationPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297
Sholl, L. M., Hirsch, F. R., Hwang, D. M., Botling, J., López‐Ríos, F., Bubendorf, L., Mino-Kenudson, M. A., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 286
Self-citationChakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 301
Pak, K., Uno, H., Kim, D. H., Tian, L., Kane, R. C., Takeuchi, M., Fu, H., Claggett, B. L., & Wei, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2797 · Cited by 276
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Devarakonda, S. H. K., Rotolo, F., Tsao, M., Lanc, I., Brambilla, E. M., Masood, A., Olaussen, K. A., Fulton, R. S., Sakashita, S., Leer, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1963 · Cited by 271
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 266
Han, J., Duan, J., Bai, H., Wang, Y., Wan, R., Wang, X., Chen, S., Tian, Y., Wang, D., Fei, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0398 · Cited by 266
Cho, J.-W., Hong, M. H., Ha, S., Kim, Y., Cho, B. C., Lee, I., & Kim, H. R. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00493-8 · Cited by 277
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D. R., Shi, H., Kelly, D. W., Patel, N., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 275
Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D., Gao, Q., Zhou, H., Liao, W., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6879 · Cited by 264
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 273
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A. A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Isomoto, K., Haratani, K., Hayashi, H., Shimizu, S., Tomida, S., Niwa, T., Yokoyama, T., Fukuda, Y., Chiba, Y., Kato, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2027 · Cited by 255
Wang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241
Riess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 242
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Hendriks, L. E. L., Henon, C., Auclin, É., Mezquita, L., Ferrara, R., Audigier-Valette, C., Mazières, J., Lefebvre, C., Rabeau, A., Moulec, S. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.009 · Cited by 240
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Campenhout, C. V., Rorive, S., Remmelink, M., Salmon, I. J., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 238
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Self-citationThe cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 239
Spigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229
Self-citationMino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 240
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Socinski, M. A., Obasaju, C. K., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.111 · Cited by 227
Self-citationTumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Steuer, C. E., & Ramalingam, S. S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8770 · Cited by 228
Duruisseaux, M., Martínez‐Cardús, A., Calleja-Cervantes, M. E., Morán, S., de Moura, M. C., Dávalos, V., Piñeyro, D., Sánchez‐Céspedes, M., Girard, N., Brevet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30284-4 · Cited by 231
Tanizaki, J., Haratani, K., Hayashi, H., Chiba, Y., Nakamura, Y., Yonesaka, K., Kudo, K., Kaneda, H., Hasegawa, Y., Tanaka, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.030 · Cited by 227
Dafni, U. G., Tsourti, Z., Vervita, K., & Peters, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.029 · Cited by 226
Self-citationHiggs, B. W., Morehouse, C. A., Streicher, K. L., Brohawn, P. Z., Pilataxi, F., Gupta, A. K., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 222
Network-based machine learning approach to predict immunotherapy response in cancer patients
Kong, J., Ha, D., Lee, J., Kim, I., Park, M., Im, S.-H., Shin, K., & Kim, S. (2022) · Nature Communications · doi:10.1038/s41467-022-31535-6 · Cited by 219
Buder‐Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 219
Dudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A., Moskovitz, M. T., Keren, S., Popovits‐Hadari, N., Urban, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.024 · Cited by 221
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02231-0 · Cited by 209
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S., Schultheis, A. M., Yu, H. A., Mandelker, D. L., Ladanyi, M., & Büttner, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 220
Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 209
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Nong, J., Gong, Y., Guan, Y., Yi, X., Yi, Y., Chang, L., Yang, L., Lv, J., Guo, Z., Jia, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05327-w · Cited by 202
Lung cancer in never smokers—the East Asian experience
Zhou, F., & Zhou, C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.14 · Cited by 217
Overview of current targeted therapy in gallbladder cancer
Song, X., Hu, Y., Li, Y., Shao, R., Liu, F., & Liu, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00324-2 · Cited by 208
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 208
MCT4-Dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-Deficient NSCLC
Qian, Y., Galán‐Cobo, A., Guijarro, I., Dang, M., Molkentine, D. P., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 206
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Self-citationClinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 197
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Wang, Q., Lian, G., Song, Y., Huang, Y., & Gong, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.040 · Cited by 195
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 200
Biomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D. H., & Drake, C. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0299-1 · Cited by 188
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Powell, S. F., Rodríguez‐Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L. G., Kopp, H., Rodríguez‐Cid, J. R., Kowalski, D. M., Cheng, Y., Kurata, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.020 · Cited by 188
Self-citationCurrent issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Barroso‐Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M. E., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 187
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 197
Kim, E. S., Velcheti, V., Mekhail, T. M., Yun, C., Shagan, S. M., Hu, S., Chae, Y. K., Leal, T. A. B., Dowell, J. E., Tsai, M. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01754-x · Cited by 183
Self-citationHinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
Desrichard, A., Kuo, F., Chowell, D., Lee, K.-W., Riaz, N., Wong, R. J., Chan, T. A.-T., & Morris, L. G. T. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy060 · Cited by 178
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Bartolacci, C., Andreani, C., do Vale, G. D., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G. W., Hodges, K. B., Starrett, J. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31963-4 · Cited by 183
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 180
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Hunter, K. A., Socinski, M. A., & Villaruz, L. C. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 178
Self-citationPD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
McGowan, E. M., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 182
Owada, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.003 · Cited by 170
Remón, J., Passiglia, F., Ahn, M., Barlési, F., Forde, P. M., Garon, E. B., Gettinger, S. N., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 171
Self-citationTumor mutation burden: from comprehensive mutational screening to the clinic
Galuppini, F., Pozzo, C. A. D., Deckert, J., Loupakis, F., Fassan, M., & Baffa, R. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0929-4 · Cited by 177
Magee, D., Hird, A. E., Klaassen, Z. W. A., Sridhar, S. S., Nam, R. K., Wallis, C. J. D., & Kulkarni, G. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.008 · Cited by 175
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
written on behalf of AME Lung Cancer Collaborative Group, Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M. Z., Dermime, S., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.09 · Cited by 170
Self-citationImmuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M. M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D. E., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 168
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Román, J. S., Morante, Z., Araujo, J. M., Gómez, H., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 167
Tumour mutational burden: clinical utility, challenges and emerging improvements
Budczies, J., Kazdal, D. N., Menzel, M., Beck, S., Kluck, K., Altbürger, C., Schwab, C., Allgäuer, M., Ahadova, A., Kloor, M., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00932-9 · Cited by 187
Self-citationUpdate on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C., Yelensky, R., Jooss, K. U., & Chan, T. A.-T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 164
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 164
Mok, T. S. K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y.-L. L. C., Gainor, J. F., Lee, S., Chiu, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01017 · Cited by 171
Sasaki, A., Nakamura, Y., Mishima, S., Kawazoe, A., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Ohtsu, A., Yoshino, T., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00922-8 · Cited by 161
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Chung, J., Dewal, N., Sokol, E. S., Mathew, P. F., Whitehead, R. P., Millis, S. Z., Frampton, G. M., Bratslavsky, G., Pal, S. K., Lee, R. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00283 · Cited by 166
Optimizing panel-based tumor mutational burden (TMB) measurement
Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D. N., Endris, V., Thomas, M., Fröhling, S., Peters, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz205 · Cited by 159
Self-citationTitin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 162
Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 166
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 159
Metadata
- Authors
- Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T. J. N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R., Villaruz, L. C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W. J., Bhagavatheeswaran, P., Chen, A. C., & Socinski, M. A.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Carbone, David P.
- Reck, Martin
- Paz-Ares, Luis
- Horn, Leora
- Felip, Enriqueta
- Ciuleanu, Tudor-Eliade
- Badin, Firas
- Ready, Neal
- Hiltermann, T. Jeroen N.
- Nair, Suresh
- Juergens, Rosalyn
- Peters, Solange
- Wrangle, John M.
- Borghaei, Hossein
- Blumenschein, George R.
- Villaruz, Liza C.
- Havel, Libor
- Chang, Han
- Geese, William J.
- Socinski, Mark A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-22
- Volume
- 376
- Issue
- 25
- Pages
- 2415-2426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6487310
- OpenAlex
- W2635951006
- Cited by
- 2,503
- References
- 20
- Citations by year
- 2026: 54 · 2025: 121 · 2024: 196 · 2023: 223 · 2022: 328 · 2021: 380 · 2020: 432 · 2019: 372 · 2018: 334 · 2017: 61
- FWCI
- 144.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (UG1CA233259, K12CA157688, P30CA016672, P30CA016058)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, non-small cell lung cancer, PD-L1 expression, first-line therapy, stage IV NSCLC, recurrent NSCLC, platinum-based chemotherapy, docetaxel, progression-free survival, overall survival, immune checkpoint inhibitors, treatment-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, PD-1/PD-L1 blockade
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Disease-Free Survival, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
